ArticleJNCI cancer spectrum2020
Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405.
Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.JNCI cancer spectrum · 2021Trial
- Association between weight loss and survival outcomes in patients with colorectal cancer: a meta-analysis.Discover oncology · 2025Review
- Impact of obesity on cancer therapy outcomes: a multicenter cohort study of 30-day mortality and morbidity.Anti-cancer drugs · 2025Article
- The role of adipogenic niche resident cells in colorectal cancer progression in relation to obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- The impact of the advanced lung cancer inflammation index on the outcomes of patients with metastatic colorectal cancer who receive chemotherapy.International journal of clinical oncology · 2023Article
- Preoperative carcinoembryonic antigen to body mass index ratio contributes to prognosis prediction in colorectal cancer.Oncology letters · 2022Article
- Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.JAMA network open · 2022Article
- Impact of Obesity on Quality of Life, Psychological Distress, and Coping on Patients with Colon Cancer.The oncologist · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 1 country.
Funding
Abstract
backgroundIn nonmetastatic colorectal cancer, overweight and mild-to-moderately obese patients experience improved outcomes compared with other patients. Obesity's influence on advanced or metastatic colorectal cancer (mCRC) is relatively unexplored.
methodsWe conducted a prospective body mass index (BMI) companion study in Cancer and Leukemia Group B (now Alliance)/SWOG 80405, a phase III metastatic colorectal cancer (mCRC) treatment trial. BMI was measured at trial registration. Primary and secondary endpoints were overall and progression-free survival, respectively. To minimize confounding by poor and rapidly declining health, we used Cox proportional hazards regression to adjust for known prognostic factors, comorbidities, physical activity, and weight loss during the 6 months prior to study entry. We also examined weight loss prior to enrollment as an independent predictor of patient outcome. All statistical tests were two-sided.
resultsAmong 2323 patients with mCRC, there were no statistically significant associations between BMI and overall or progression-free survival (adjusted
conclusionsIn this prospective study of patients with mCRC, BMI at time of first-line chemotherapy initiation was not associated with patient outcome. Weight loss prior to study entry was associated with increased risk of patient mortality and disease progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.